Aurinia Pharmaceuticals Inc · NASDAQ:AUPH
Aurinia Pharmaceuticals — Investor Presentation (August 2026)
35 slides from Aurinia Pharmaceuticals's investor presentation, August 2026
Slide 1: Corporate Presentation
® Corporate Presentation August 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable U.S. securities law and forward-looking information within the meaning of applicable Canadian securities law. We caution investors that forward-looking statements are based on management
Slide 3: Changing the Trajectory of Autoimmune Diseases
Continue LUPKYNIS Changing the Accelerate LUPKYNIS® commercialization commercial by improving growth screening, diagnosis and Trajectory of treatment rates Autoimmune Diseases Advance AUR200 Advance aritinercept development program commercialization Accelerate LUPKYNIS® development by improving scre
Slide 4: Recent Financial Results
Recent Financial Results \ Aurinia’
Slide 5: Results for the Six Months Ended June 30
Results for the Six Months Ended June 30 Six Months Ended June 30 % Change 2026 2025 Total Revenue $160.9 million $132.5 million 21% Net Product Sales $153.0 million $126.5 million 21% Net Income $71.8 million $44.9 million 60% Diluted Earnings per Share $0.53 $0.32 66% Cash Flows from Operating Act
Slide 6: 2026 Financial Guidance
2026 Financial Guidance Net Product Sales $315.0M Guidance Range a $305.0M $271.3M $315 million to $325 million Total Revenue $216.2M (up 11% to 15%) $158.5M $305 million to $315 million Net Product Sales (up 12% to 16%) $103.5M $45.5M 2021 2022 2023 2024 2025 2026 Guidance Range a ® a Guidance as o
Slide 7: LUPKYNIS
LUPKYNIS® A calcineurin inhibitor (CNI) indicated in combination with a background immunosuppressive regimen for the treatment of adult patients with active lupus nephritis The first oral therapy approved for the treatment of lupus nephritis ®
Slide 8: Lupus Nephritis Is Among the Most Severe Complications of SLE
Lupus Nephritis (LN) Is Among the Most Severe and Dangerous Complications of Systemic Lupus Erythematosus (SLE) • SLE, commonly known as lupus, is a chronic autoimmune disease where the body's immune system mistakenly attacks its own healthy tissues and organs • Over 200,000 people in the United Sta
Slide 9: Proteinuria Reduction Is Associated with Long-Term Renal Preservation
Proteinuria Reduction Is Associated with Long-Term Renal Preservation Kidney Survival Based on Proteinuria Response Status a, b The larger the initial reduction in proteinuria in the first several months of management, the lower the risk of ESKD ESKD=end-stage kidney disease a Adapted with permissio
Slide 10: 2024 ACR LN Treatment Guideline Emphasizes Early and Aggressive Treatment
2024 ACR LN Treatment Guideline Emphasizes Early and Aggressive Treatment to Preserve Kidney Function a • Specifically, this updated guideline now details the following: Triple immunosuppressive therapy, including a calcineurin Goal is complete renal Reduce corticosteroid dose to inhibitor (CNI) or
Slide 11: LUPKYNIS Is a Novel, Structurally Modified CNI with a Dual Mechanism
LUPKYNIS Is a Novel, Structurally Modified CNI that Targets LN with a Dual Mechanism of Action DUAL MECHANISM T CELL CONTROL PODOCYTE SUPPORT Immune Modulation Kidney Filter Protection Inhibits IL-2 mediated T cell activation and Stabilizes podocyte structure IFN-γ mediated inflammatory response ® 1
Slide 12: Robust Clinical Study History
Robust Clinical Study History Improved Complete Renal Response Rate AURA-LV Randomized Phase 2 Study in 265 Patients AURORA 1 Randomized Phase 3 Study in 357 Patients Established AURORA 2 Safety Rapid Randomized Extension Study in 216 Patients Profile Proteinuria Reduction ® 12
Slide 13: Significantly More Patients on LUPKYNIS Achieved a Complete Renal Response
Significantly More Patients on LUPKYNIS Achieved a Complete Renal Response in AURORA 1 as Early as Week 24 a Complete Renal Response at Week 52 Complete Renal Response at Week 24 Patients Achieving Complete Renal Response at Week 52, % Patients Achieving Complete Renal Response at Week 24, % 100 (Pr
Slide 14: LUPKYNIS Rapidly Reduced Proteinuria in Fewer Days in AURORA 1
LUPKYNIS Rapidly Reduced Proteinuria in Fewer Days in AURORA 1 a UPCR ≤0.5 mg/mg in <6 Months b 50% UPCR Reduction in 29 Days b 400 70 350 60 34 372 days 203 63 days 300 50 fewer Days, median Days, median fewer 250 days days 40 200 30 150 169 days 29 days 20 100 50 10 0 0 LUPKYNIS + MMF + Placebo +
Slide 15: New Analysis Shows Reduced Risk of Renal-Related Event or Death
New Analysis (EULAR 2026) a Shows LUPKYNIS Associated with 53% Reduction in Risk of Renal-Related Event or Death Time to Renal-Related Event or Death b (AURORA 1 Phase 3 Population) 50 Treatment Events (%) HR (95% CI) P-value LUPKYNIS 45 Placebo LUPKYNIS 28 (15.7) 0.467 (0.296, 0.736) 0.0007 40 Cens
Slide 16: Adverse Reactions in AURORA 1 and AURA-LV
Adverse Reactions Occurring in ≥3% of Patients Treated with LUPKYNIS 23.7 mg Twice a Day and ≥2% Higher than Placebo in AURORA 1 and AURA-LV a LUPKYNIS 23.7 mg Twice a Day + Placebo + Adverse Reaction MMF + Corticosteroids MMF + Corticosteroids (n=267) (n=266) Glomerular Filtration Rate Decreased 26
Slide 17: PRESERVE: Phase 4 Study of LUPKYNIS in Combination Therapy
PRESERVE: A Multi-Center Phase 4 Study of the Efficacy and Safety of LUPKYNIS in Combination with Belimumab, Obinutuzumab or Anifrolumab at Inducing Rapid Renal Response in Patients with Lupus Nephritis ®
Slide 18: Majority of LN Patients Do Not Achieve Proteinuria Control with Any Regimen
While LUPKYNIS Results Are the Strongest, the Majority of LN Patients Do Not Achieve Proteinuria Control as Measured by CRR at Week 24 with Any Regimen Complete Renal Response at Week 24 35 LUPKYNIS Belimumab Obinutuzumab Complete Renal Response, % 30 32.4% ∆ 12.7% ∆ 0% 25 ∆ 3% 24% 24% 20 22% 19.7%
Slide 19: Complementary Mechanisms: Voclosporin and Belimumab
Complementary Mechanisms May Work in Concert to Enhance Efficacy Voclosporin Belimumab T follicular helper cells signal the activation of B cells Inhibits: Inhibits BAFF • IL-2 mediated T cell activation • IFN-γ mediated inflammatory response Immature Downregulates B cells B Cell Mature B Cell T Cel
Slide 20: Complementary Mechanisms: Voclosporin and Obinutuzumab
Complementary Mechanisms May Work in Concert to Enhance Efficacy Voclosporin Obinutuzumab T follicular helper cells signal the activation of B cells Targets CD20 antigens Inhibits: • IL-2 mediated T cell activation • IFN-γ mediated inflammatory response Immature Depletes immature and B Cell mature B
Slide 21: Complementary Mechanisms: Voclosporin and Anifrolumab
Complementary Mechanisms May Work in Concert to Enhance Efficacy Voclosporin Anifrolumab T follicular helper cells Inhibits: Plasmacytoid signal the activation of dendritic cell Inhibits type 1 • IL-2 mediated T cell activation B cells interferon signaling • IFN-γ mediated inflammatory response Type
Slide 22: PRESERVE Study Schema
PRESERVE Study Schema Screening Period Treatment Period Follow-Up Period (up to 4 weeks) a (24 weeks) (4 weeks) Key Eligibility Criteria Treatment Regimen (N=150) Endpoints • Adult (18-75 years old) LUPKYNIS + Primary Endpoint: • Diagnosed with SLE Belimumab per USPI according to 2019 • CRR at 24 we
Slide 23: Aritinercept
Aritinercept A dual BAFF/APRIL inhibitor for the potential treatment of autoimmune diseases ®
Slide 24: Aritinercept Is a Dual BAFF/APRIL Inhibitor
Aritinercept Is a Dual BAFF/APRIL Inhibitor • Aritinercept contains a BCMA-engineered extracellular binding domain optimized for APRIL BAFF superior affinity to BAFF and APRIL (others use TACI-engineered extracellular binding domain) Engineered extracellular domain of BCMA receptor − BCMA has a stro
Slide 25: Role of BAFF and APRIL
Role of BAFF and APRIL • BAFF and APRIL are important cytokines that regulate B cell survival and differentiation, whose targets are expressed on B cells at different stages of B cell development a • Targeting both BAFF and APRIL depletes a broader set of B cells, including plasma cells, than target
Slide 26: Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor
Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor a BAFF APRIL Drug (Sponsor) Compared to Compared to Kd (pM) Kd (pM) Aritinercept Aritinercept Aritinercept 147 N/A 28 N/A (Aurinia) Atacicept 856 5.8x 54 1.9x (Vera) Telitacicept 609 4.1x 74 2.6x (RemeGen/Vor Bio) Aritinercept has high bindin
Slide 27: Aritinercept Potently Inhibits BAFF- and APRIL-Mediated B Cell Proliferation
Aritinercept Potently Inhibits BAFF- and APRIL-Mediated B Cell Proliferation a B Cell Proliferation in the Presence of BAFF B Cell Proliferation in the Presence of APRIL Aritinercept Relative Luminescence Units (RLUs) Relative Luminescence Units (RLUs) Aritinercept Atacicept Atacicept Telitacicept T
Slide 28: Aritinercept Single Ascending Dose (SAD) Study: Design
Aritinercept Single Ascending Dose (SAD) Study: Design Screening (up to 5 weeks), In-Clinic Phase (1 week) and Out-Patient Visits (13 weeks) Dose Level 6 (n=8 Healthy Subjects) Screening 300 mg SC Placebo n=6 n=2 Dose Level 5 (n=8 Healthy Subjects) Screening 225 mg SC Placebo n=6 n=2 Dose Level 4 (n
Slide 29: Aritinercept SAD Study: Safety Summary
Aritinercept SAD Study: Safety Summary • Aritinercept was well tolerated at all dose levels tested • No treatment-related Grade ≥3 adverse events a • No treatment-related serious adverse events (SAEs) a • No discontinuations due to treatment-related adverse events • Adverse events that occurred in m
Slide 30: Single Doses Led to Robust and Long-Lasting Reductions in Immunoglobulins
Aritinercept SAD Study: Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins in Humans IgA IgM IgG 20% 20% 20% Mean Change from Baseline 0% 0% 0% -20% -20% -20% -40% -40% -40% Mean IgA reductions Mean IgM reductions Mean IgG reductions of up to 48% of up to 55% o
Slide 31: Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA Reductions in IgA a 20% Mean % Change Drug from Baseline in IgA (Sponsor) at Day 28 a Mean Change from Baseline 0% Aritinercept -48% (Aurinia) Povetacicept -20% -43% (Vertex) Sibeprenlimab -41% (Otsuka) -40% Atacicept -10% (Vera) Telitacicept -
Slide 32: Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM Reductions in IgM a 20% Mean % Change Drug from Baseline in IgM (Sponsor) at Day 28 a Mean Change from Baseline 0% Aritinercept -55% (Aurinia) Povetacicept -20% -52% (Vertex) Sibeprenlimab -39% (Otsuka) -40% Atacicept -17% (Vera) Telitacicept -
Slide 33: Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG Reductions in IgG a 20% Mean % Change Drug from Baseline in IgG (Sponsor) at Day 28 a Mean Change from Baseline 0% Aritinercept -20% (Aurinia) Povetacicept -20% -19% (Vertex) Sibeprenlimab -13% (Otsuka) -40% Atacicept N/A b (Vera) Telitacicept
Slide 34: Summary and Next Steps
Summary and Next Steps • Aritinercept was well tolerated at all dose levels tested • Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins supportive of once-monthly dosing • Aritinercept is now in clinical development for four potential indications and has therap
Slide 35: © Aurinia Pharmaceuticals Inc., 2026. All rights reserved. Trademarks and logos are the property
® © Aurinia Pharmaceuticals Inc., 2026. All rights reserved. Trademarks and logos are the property of Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals — Investor Presentation (August 2026) on 6ix